The feasibility study of 64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer

被引：0
|
作者：
Yonemori, Kan [1 ]
Tamura, Kenji [1 ]
Kurihara, Hiroaki [3 ]
Kono, Yuzuru [3 ]
Arai, Yasuaki [3 ]
Wada, Yasuhiro [2 ]
Takahashi, Kazuhiro [3 ]
Hasegawa, Koki [3 ]
Watanabe, Yasuyoshi [3 ]
Fujiwara, Yasuhiro [1 ]
机构：
[1] Natl Canc Ctr Hosp Tokyo, Breast & Med Oncol, Tokyo, Japan
[2] RIKEN, Ctr Mol Imaging Sci, Kobe, Hyogo, Japan
[3] Natl Canc Ctr Hosp Tokyo, Nucl Med, Tokyo, Japan
来源：
JOURNAL OF NUCLEAR MEDICINE | 2012年 / 53卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
1266
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Continued trastuzumab therapy for patients with HER2-positive breast cancer
    Haslbauer, F.
    EJC SUPPLEMENTS, 2008, 6 (07): : 221 - 221
  • [32] Trastuzumab (herceptin) and HER2-positive breast cancer
    Murray, S
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2006, 174 (01) : 36 - 37
  • [33] Trastuzumab emtansine for HER2-positive breast cancer
    Venkatesan, Priya
    LANCET ONCOLOGY, 2016, 17 (12): : E528 - E528
  • [34] Adjuvant trastuzumab for HER2-positive breast cancer
    Spicer, J
    Harries, M
    Ellis, P
    LANCET, 2005, 366 (9486): : 634 - 634
  • [35] HER2-Positive Breast Cancer: Beyond Trastuzumab
    Murphy, Conleth G.
    Fornier, Monica
    ONCOLOGY-NEW YORK, 2010, 24 (05): : 410 - 415
  • [36] Observational study on adjuvant trastuzumab in HER2-positive early breast cancer patients
    Mustacchi, G.
    Puglisi, F.
    Molino, A. M.
    Crivellari, D.
    Ghiotto, C.
    Ferro, A.
    Brunello, A.
    Saracchini, S.
    Turazza, M.
    Cretella, E.
    Iop, A.
    Malagoli, M.
    Stefani, M.
    FUTURE ONCOLOGY, 2015, 11 (10) : 1493 - 1500
  • [37] Retreatment with trastuzumab in Her2-positive metastatic breast cancer patients:: a clinical study
    Carabantes-Ocon, F.
    Saez-Lara, E.
    Burgos-Garcia, L.
    Villar-Chamorro, E.
    Casaus-Hazanas, A.
    Luna, S.
    Martinez, C.
    BREAST CANCER RESEARCH, 2007, 9 (01)
  • [38] Retreatment with trastuzumab in Her2-positive metastatic breast cancer patients: a clinical study
    F Carabantes-Ocón
    E Saez-Lara
    L Burgos-Garcia
    E Villar-Chamorro
    A Casaus-Hazañas
    S Luna
    C Martínez
    Breast Cancer Research, 9
  • [39] MicroSPECT/CT and MicroPET Imaging of Human Breast Cancer Xenografts Expressing HER2 in Athymic Mice using 111In-and 64Cu-DOTA-Trastuzumab Fab
    Chan, C.
    Scollard, D. A.
    McLarty, K.
    Smith, S.
    Reilly, R. M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S477 - S477
  • [40] Relationship between 64Cu-DOTA-trastuzumab positron emission tomography uptake and assessment of HER2 by immunohistochemistry in women with advanced breast cancer
    Mortimer, J. E.
    Colcher, D.
    Frankel, P.
    Raubitschek, A.
    Carroll, M.
    Conti, P.
    Tong, S.
    Poku, K.
    Miles, J.
    Bading, J.
    CANCER RESEARCH, 2013, 73
12345